This work is licensed under a Creative Commons Attribution 4.0 International License.
Bac5 (1-17)[F2,15W; P4R]
General Information
DCTPep ID DCTPep00899
Peptide Name Bac5 (1-17)[F2,15W; P4R]
Sequence RWRRPIRRPPIRPPWYP
Sequence Length 17
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Cancer therapy related peptides
Activity Information
| Cell Line | Disease | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|
| MEC-1 | Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia | 17% Killing=32µM | MTT assay | 20h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure DCTPep00899
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C109H167N37O19
Absent amino acids ACDEFGHKLMNQSTV
Theoretical pI 12.30
Acidic residues 0
Basic residues 6
Polar residues 1
Molecular weight (Average) 2299.76
Molecular weight (Monoisotopic) 2298.32
Common amino acids PR
Net charge 6
Instability index (II) 172.71
Aliphatic index 45.88
Grand average of hydropathicity (GRAVY) -1.806
Half Life
1 hours (mammalian reticulocytes, in vitro).
2 min (yeast, in vivo).
2 min (Escherichia coli, in vivo).
Extinction coefficients
Ext. coefficient 12490
Abs 0.1% (=1 g/l) 5.431
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 31692278
Title Proline-Rich Peptides With Improved Antimicrobial Activity Against E. Coli, K. Pneumoniae, and A. Baumannii.
Year 2019
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.